CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 27 enrolled
Drug / intervention
gonadotropin releasing hormone (GnRH)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00493961
NCT00493961Phase 1Completed
CompareCT.gov

The Effects of 7 Days of Exogenous Pulsatile GnRH Treatment on the Pituitary-Gonadal Axis in Hypogonadotropic Hypogonadal Subjects

Massachusetts General Hospital·interventional·Posted Jun 29, 2007·Updated Jul 1, 2022

In Brief

A Phase 1 clinical trial evaluating gonadotropin releasing hormone (GnRH) for Kallmann Syndrome and 2 related conditions. Completed, enrolled 27 participants across 1 site.

Detailed Summary

Men with Idiopathic Hypogonadotropic Hypogonadism (IHH) lack a hormone called gonadotropin releasing hormone (GnRH). This hormone is important for starting puberty, maintaining testosterone levels, and fertility. The purpose of this study is to research the effects of treating IHH men with GnRH for 7 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKallmann Syndrome, Idiopathic Hypogonadotropic Hypogonadism, GnRH Deficiency
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 29, 2007
Enrollment StartJan 1, 1999
Primary CompletionNov 17, 2009
TodayJul 2, 2026
Enrollment to primary: 10.9 yearsPosted 19.0 years ago

Interventions

gonadotropin releasing hormone (GnRH)drug

Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)